Quarterly report pursuant to Section 13 or 15(d)

Note 14 - Segments (Tables)

v3.20.2
Note 14 - Segments (Tables)
9 Months Ended
Sep. 30, 2020
Notes Tables  
Schedule of Segment Reporting Information, by Segment [Table Text Block]
T
hree Months Ended
September
30
, 2020
 
Diagnostics
   
Therapeutics
   
Corporate
   
Total
 
Royalty revenue
  $
2,047
    $
    $
    $
2,047
 
License revenue
   
4,726
     
     
     
4,726
 
Grant and other revenue
   
106,729
     
154,887
     
     
261,616
 
Total revenue
   
113,502
     
154,887
     
     
268,389
 
Cost of revenue
   
82
     
     
     
82
 
Research and development expenses
   
1,251,383
     
126,615
     
     
1,377,998
 
Selling, general and administrative expenses, excluding depreciation and amortization
(1)
   
     
     
1,773,532
     
1,773,532
 
Depreciation and amortization
(2)
   
4,027
     
     
11,375
     
15,402
 
(Loss) income from operations
(3)
   
(1,268,605
)
   
28,272
     
(1,784,907
)
   
(2,898,625
)
Other expense
(4)
   
     
     
(713
)
   
(713
)
Net (loss) income
   
(1,141,990
)
   
28,272
     
(1,785,620
)
   
(2,899,338
)
Total assets, net of depreciation and amortization:
                               
United States
  $
1,000
    $
38,320
    $
5,839,733
    $
5,879,053
 
International
   
116,782
     
     
     
116,782
 
Capital expenditures
   
120,810
     
     
     
120,810
 
T
hree Months Ended
September
30, 2019
 
Diagnostics
   
Therapeutics
   
Corporate
   
Total
 
Royalty revenue
  $
4,895
    $
    $
    $
4,895
 
Grant and other revenue
   
77,049
     
154,867
     
     
231,916
 
Total revenue
   
81,944
     
154,867
     
     
236,811
 
Cost of revenue
   
195
     
     
     
195
 
Research and development expenses
   
1,678,423
     
123,135
     
     
1,801,558
 
Selling, general and administrative expenses, excluding depreciation and amortization
(1)
   
     
1,052
     
1,484,155
     
1,485,207
 
Depreciation and amortization
(2)
   
     
     
34,289
     
34,289
 
(Loss) income from operations
(3)
   
(1,596,674
)
   
30,680
     
(1,518,444
)
   
(3,084,438
)
Other income
(4)
   
     
     
10,334
     
10,334
 
Income tax (expense) benefit
   
(72
)
   
16
     
55
     
 
Net (loss) income
   
(1,596,746
)
   
30,696
     
(1,508,055
)
   
(3,074,104
)
Total assets, net of depreciation and amortization:
                               
United States
  $
36,811
    $
93,860
    $
4,688,379
    $
4,819,050
 
International
   
2,606
     
     
     
2,606
 
Nine Months Ended September 30, 2020
 
Diagnostics
   
Therapeutics
   
Corporate
   
Total
 
Royalty revenue
  $
26,188
    $
    $
    $
26,188
 
License revenue
   
4,726
     
     
     
4,726
 
Grant and other revenue
   
381,103
     
283,745
     
     
664,848
 
Total revenue
   
412,017
     
283,745
     
     
695,762
 
Cost of revenue
   
1,048
     
     
     
1,048
 
Research and development expenses
   
3,402,160
     
256,886
     
     
3,659,046
 
Selling, general and administrative expenses, excluding depreciation and amortization
(1)
   
     
(550
)
   
4,895,328
     
4,894,778
 
Depreciation and amortization
(2)
   
4,027
     
     
47,474
     
51,501
 
(Loss) income from operations
(3)
   
(2,995,218
)
   
27,409
     
(4,942,802
)
   
(7,910,611
)
Other income
(4)
   
     
     
12,045
     
12,045
 
Net (loss) income
   
(2,995,218
)
   
27,409
     
(4,930,757
)
   
(7,898,566
)
Total assets, net of depreciation and amortization:
                               
United States
  $
1,000
    $
38,320
    $
5,839,733
    $
5,879,053
 
International
   
116,782
     
     
     
116,782
 
Capital expenditures
   
120,810
     
     
8,406
     
129,216
 
Nine
Months Ended
September
30, 2019
 
Diagnostics
   
Therapeutics
   
Corporate
   
Total
 
Royalty revenue
  $
13,985
    $
    $
    $
13,985
 
License revenue
   
9,953
     
     
     
9,953
 
Grant and other revenue
   
309,670
     
204,919
     
     
514,589
 
Total revenue
   
333,608
     
204,919
     
     
538,527
 
Cost of revenue
   
6,559
     
     
     
6,559
 
Research and development expenses
   
3,194,468
     
418,315
     
     
3,612,783
 
Selling, general and administrative expenses, excluding depreciation and amortization
(1)
   
     
15,828
     
4,985,990
     
5,001,818
 
Depreciation and amortization
(2)
   
     
     
107,794
     
107,794
 
Loss from operations
(3)
   
(2,867,419
)
   
(229,224
)
   
(5,093,784
)
   
(8,190,427
)
Other income
(4)
   
     
     
17,456
     
17,456
 
Provision for income tax
   
(248
)
   
(20
)
   
(439
)
   
(707
)
Net loss from continuing operations
   
(2,867,667
)
   
(229,244
)
   
(5,076,767
)
   
(8,173,678
)
Loss from discontinued operations, net of tax
   
(2,665
)
   
     
     
(2,665
)
Net loss
   
(2,870,332
)
   
(229,244
)
   
(5,076,767
)
   
(8,176,343
)
Total assets, net of depreciation and amortization:
                               
United States
  $
36,811
    $
93,860
    $
4,688,379
    $
4,819,050
 
International
   
2,606
     
     
     
2,606